Century Therapeutics, Inc.
IPSC
Rank in Stocks
#14378
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering... Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Share Price
$1.81
Last synced: 2026-11-09
Market Cap
$327.75M
Change (1 day)
7.74%
Change (1 year)
221.32%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Century Therapeutics, Inc. (IPSC)
Category
Healthcare
Operating Margin for Century Therapeutics, Inc. (IPSC)
Operating Margin as of November 2026 TTM: 0.00%
According to Century Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -13.78%.
Operating Margin history for Century Therapeutics, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -13.78% | -99.34% |
| 2024 | -2,096.48% | -68.03% |
| 2023 | -6,556.87% | 154.72% |
| 2022 | -2,574.17% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Century Therapeutics, Inc.'s operating margin
What was Century Therapeutics, Inc.'s operating margin in 2025?
In 2025, Century Therapeutics, Inc.'s operating margin was -13.78%, compared with -2,096.48% in 2024.
How has Century Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Century Therapeutics, Inc.'s operating margin was highest in 2021 (0.00%) and lowest in 2023 (-6,556.87%).
How does Century Therapeutics, Inc.'s operating margin compare with similar companies?
Century Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.